AU4565000A - Organic compounds - Google Patents

Organic compounds

Info

Publication number
AU4565000A
AU4565000A AU45650/00A AU4565000A AU4565000A AU 4565000 A AU4565000 A AU 4565000A AU 45650/00 A AU45650/00 A AU 45650/00A AU 4565000 A AU4565000 A AU 4565000A AU 4565000 A AU4565000 A AU 4565000A
Authority
AU
Australia
Prior art keywords
recipient
rejection
xenografts
pharmaceutical composition
body fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45650/00A
Other languages
English (en)
Inventor
Paolo Brenner
Emanuele Luigi Maria Cozzi
Peter John Friend
Francoise Richard
Guy Taccard
John Wallwork
David James Graham White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910835.9A external-priority patent/GB9910835D0/en
Priority claimed from GBGB9925443.5A external-priority patent/GB9925443D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU4565000A publication Critical patent/AU4565000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU45650/00A 1999-05-10 2000-05-10 Organic compounds Abandoned AU4565000A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9910835.9A GB9910835D0 (en) 1999-05-10 1999-05-10 Organic compounds
GB9910835 1999-05-10
GB9925443 1999-10-27
GBGB9925443.5A GB9925443D0 (en) 1999-10-27 1999-10-27 Organic compounds
PCT/EP2000/004250 WO2000067773A2 (en) 1999-05-10 2000-05-10 Combinations of immunosupressive agents for the treatment or prevention of graft rejections

Publications (1)

Publication Number Publication Date
AU4565000A true AU4565000A (en) 2000-11-21

Family

ID=26315533

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45650/00A Abandoned AU4565000A (en) 1999-05-10 2000-05-10 Organic compounds

Country Status (7)

Country Link
US (5) US20020132764A1 (enExample)
EP (2) EP1980263A1 (enExample)
JP (1) JP2002544167A (enExample)
AT (1) ATE474590T1 (enExample)
AU (1) AU4565000A (enExample)
DE (1) DE60044717D1 (enExample)
WO (1) WO2000067773A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE222502T1 (de) * 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
ATE475418T1 (de) 2000-01-14 2010-08-15 Univ Pennsylvania O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
BR112016006378A2 (pt) 2013-09-24 2017-08-01 Giner Inc sistema para tratamento de gás de um implante de célula
WO2018093956A1 (en) 2016-11-15 2018-05-24 Giner, Inc. Percutaneous gas diffusion device suitable for use with a subcutaneous implant
JP7199632B2 (ja) 2017-05-04 2023-01-06 ガイナー，インク． 堅牢なインプラント可能なガス送達装置ならびにそれを含む方法、システムおよび装置

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178858A (en) * 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
US5135934A (en) 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5651968A (en) * 1991-08-23 1997-07-29 Alberta Research Council Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5843452A (en) * 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
CA2190268C (en) 1994-05-13 2000-01-25 Wolfgang Bohm Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
IL115742A (en) 1994-10-26 2000-06-01 Novartis Ag Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
US5697109A (en) 1994-10-28 1997-12-16 Barton Medical Corporation Patient transport system
US5631282A (en) * 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
ATE222502T1 (de) * 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
GB9619706D0 (en) 1996-09-20 1996-11-06 Pharmacia Spa Synergistic immunosuppressant composition containing a 2,2'-bi-1H-pyrrole comp und
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
DE69835201T2 (de) 1997-04-18 2007-06-14 Novartis Ag Neoglycoproteine
US6825395B1 (en) * 1997-07-14 2004-11-30 Nippon Meat Packers, Inc. Transgenic non-human mammals expressing the human complement inhibitor (DAF/CD55)

Also Published As

Publication number Publication date
WO2000067773A3 (en) 2001-06-28
EP1181034B1 (en) 2010-07-21
DE60044717D1 (de) 2010-09-02
US20050277585A1 (en) 2005-12-15
EP1980263A1 (en) 2008-10-15
US20110142953A1 (en) 2011-06-16
US20070060511A1 (en) 2007-03-15
JP2002544167A (ja) 2002-12-24
US20080199478A1 (en) 2008-08-21
ATE474590T1 (de) 2010-08-15
WO2000067773A2 (en) 2000-11-16
EP1181034A2 (en) 2002-02-27
US8435520B2 (en) 2013-05-07
US20020132764A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
GB9917406D0 (en) Compounds
MXPA03006557A (es) METODO Y APARATO PARA REMOVER SUSTANCIAS DE LOS VASOS DEL CORAZON Y OTRAS PARTES DEL CUERPO, PARA MINIMIZAR O EVITAR DAnOS O DISFUNCIONES RENALES U OTROS.
PT1293207E (pt) Utilização de ritonavir (abt-538) para melhoria da farmacocinética de drogas metabolizadas por citocromo p450 num método de tratamento da sida
EP1231887A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF SCARS
ES2110320T3 (es) Dispositivo de tratamiento de la superficie de carrocerias de vehiculos.
IL149995A (en) Depsipeptides and pharmaceutical compositions containing the same
WO1998033491A3 (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
WO2002100148A3 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
WO2002078684A3 (en) Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
AU4565000A (en) Organic compounds
BG105664A (en) Use of apomophines for the treatment of organic erectile dysfunction in males
ATE374617T1 (de) Verfahren zur herstellung eines bluddrucksenkenden mittel enthaltenden ein dipeptid als wirksames bestandteil
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
AU8216691A (en) Autobiotics and their use in eliminating nonself cells in vivo
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
WO2005060960A3 (en) Use of histamine to treat bone disease
AU5740796A (en) Use of fluidized bed reactors for treatment of wastes contai ning organic nitrogen compounds
CA2430467A1 (en) Means and method for treating an intimal dissection after stent implantation
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
GB9919713D0 (en) New medical use of high density lipoprotein
EP0910375A4 (en) COMPOSITION BASED ON ENALAPRIL AND LOSARTAN
GB9004348D0 (en) New use of catechol derivatives and their physiologically acceptable salts and esters
RU98109220A (ru) Способ лечения экземы
BG106831A (en) Compound and method for the treatment of pain
AU2202301A (en) Cd45 inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase